Display Of IP Strength In China: Lilly Wins Patent Dispute For Cialis Against Domestic Chinese Company
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Eli Lilly's win of the patent infringement suit in China against Jiangyin Dongfang Pharmaceutical for manufacturing tadalafil, the active ingredient in Lilly's male erectile dysfunction drug Cialis, is good news for multinational companies operating in China